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Abstract  
Prostate cancer is initially treated via androgen deprivation therapy (ADT), a highly 
successful treatment in the initial pursuit of tumor regression, but commonly restricted by the 
eventual emergence of a more lethal ‘castrate resistant’ form of the disease. Intracrine 
pathways that utilize dehydroepiandrosterone (DHEA) or other circulatory precursor steroids, 
are thought to generate relevant levels of growth-stimulating androgens such as 
testosterone (T) and dihydrotestosterone (DHT). In this study, we explored the capacity of 
the active vitamin D hormone to interact and elicit changes upon this prostatic intracrine 
pathway at a metabolic level. We used androgen dependent LNCaP cells cultured under 
steroid-depleted conditions and assessed the impact of vitamin D-based compounds upon 
intracrine pathways that convert exogenously added DHEA to relevant metabolites, through 
Mass Spectrometry (MS). Changes in relevant metabolism-related gene targets were also 
assessed. Our findings confirm that exposure to vitamin D based compounds, within LNCaP 
cells, elicits measurable and significant reduction in the intracrine conversion of DHEA to T, 
DHT and other intermediate metabolites within the androgenic pathway. The aassessment 
and validation of the biological model and analytical platforms were performed by 
pharmacological manipulations of the SRD5α and HSD-17β enzymes. The data provides 
further confirmation for how a vitamin D-based regime may be used to counter intracrine 
mechanisms contributing to the emergence of castrate-resistant tumors. 
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Abbreviations  
MALDI: Matrix Assisted Laser desorption ionization 
FTICRMS: Fourier-transform ion cyclotron resonance mass spectrometry 
T: Testosterone 
DHT: Dihydrotestosterone 
1. Introduction  
Androgen deprivation therapy (ADT) is a treatment option for high risk, locally advanced 
or metastatic forms of prostate cancer (PC) [1,2]. It facilitates the reduction of 
bioavailable activating androgen receptor (AR) ligands, such as testosterone (T) and 
dihydrotestosterone (DHT) [3] that promote tumor growth. The initial clinical responses to 
ADT are highly favorable but temporal, and often associated with relapse to a lethal 
castrate resistant form of the disease (CRPC) with a tumor phenotype that still retains an 
active AR-mediated pathway [3,4], despite the low serum levels of T. Various 
mechanisms thought to underpin this recurrence have been proposed and reviewed that 
include; hypersensitivity through amplification or mutations within the AR gene [5-7], 
recruitment of co-activators, and altered steroidogenesis [8,9]. While these processes 
may each in part contribute to CRPC, there is increasing evidence that retained 
androgen signaling within the tumor may be significantly driven through uptake of 
circulating adrenal steroids, such as dehydroepiandrosterone (DHEA), and their 
subsequent intracrine conversion to AR-activating ligands [10,11]. Delineating the 
genetic changes and protein functions that drive such adaptive metabolic networks 
represents a challenge for the future development of therapeutic regimens based upon 
enzymatic inhibition and manipulated expression of encoding target genes [9,12,13]. 
While evidence support vitamin D may protect against prostate cancer initiation [14], its 
potential as a treatment for more aggressive forms of the disease and how it may 
interact with androgen pathways, is less clear. The vitamin D receptor (VDR) is 
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appreciably expressed in prostate [15,16] with the hormonally active form of vitamin D3, 
1,25-dihydroxyvitamin-D3 (1,25D) shown to regulate the gene expression of 
components that may dictate the flux of steroid hormone metabolic pathways (Figure 1) 
[17].  Our group has previously described the capacity of ligand-activated VDR to 
enhance expression of the cytochrome P450 genes, CYP3A4 and CYP3A5, leading to 
an increased level of metabolic inactivation of testosterone and DHEA within LNCaP and 
LAPC-4 prostate cancer cells [18,19]. These CYP3A enzymes have been found to cause 
hydroxylation of steroidal compounds that include testosterone, DHEA, androstenedione 
(A4) and dihydrotestosterone (DHT) [20-22]. These findings indicate that the selective 
regulation of CYP3A and other metabolism-related genes through a vitamin D-based 
regimen, may represent a novel therapeutic approach that applied in combination with 
ADT, could enable simultaneous targeting of the bioavailability of both serum and 
tumoral androgens. This concept is supported through clinical studies that suggest 
patients with a higher level of CYP3A4 expression in prostate tissue have a more 
successful chance of cancer specific survival and lower levels of relapse PSA (prostate 
specific antigen), indicating towards a positive link with upregulation and cancer 
suppression [23].  
In this study, we expand upon our previous reports and assess how ligand activated 
VDR within prostate cancer cells may impact upon the intracrine biosynthesis of 
androgens generated from exogenously derived DHEA. Through application of a mass 
spectrometry platform used in combination with specific enzymatic inhibitors and 
expression analysis of key metabolic genes, we assess the conversion of specific 
androgens within our metabolic system, and evaluate the potential mechanisms through 
which VDR-mediated effects modulate pathways that dictate the endogenous levels of 
activating AR ligands. 
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2. Materials and Methods 
2.1. Cell culture and ligands  
LNCaP cell line were obtained from the European Collection of Authenticated Cell 
Cultures (LNCaP clone FGC (ECACC 89110211)) and maintained in RPMI 1640 with 
10% foetal bovine serum (FBS), 1% Penicillin/Streptomycin and 1% L-Glutamine 
(GIBCO, Invitrogen). For experiments using steroid depleted conditions, cells were 
supplemented with Phenol-red free RPMI (PRF-RPMI) with 5% charcoal stripped serum 
(CSS) (GIBCO, Invitrogen). All cells were routinely maintained at 37°C with 5% CO2. All 
nuclear receptor ligands were dissolved in ethanol (vehicle) and included; 1,25-
dihydroxyvitamin-D3 (Sigma, UK), EB1089 (Tocris Bioscience, UK) and DHEA (TCI 
Europe). Hydroxydehydroepiandrosterone (mixisomers), testosterone, androstenedione, 
5-androstanedione, dihydrotestosterone, hydroxytestosterone (mixisomers) were 
obtained from Steraloids (Newport, US). Enzymatic inhibitions were through application 
of ritonavir, kindly provided by Professor Andrew Owen, University of Liverpool, with 
Finasteride and 2,4-dihydroxybenzophenone and Girard Reagent purchased from 
Sigma, UK and Testosterone-2,3,4-13C3 from Cerilliant, USA. 
2.2. Cell Culture treatments  
LNCaP cells were seeded in standard growth media at 2 x 106 cells/flask (medium-
T75cm3 flask) and incubated at 37°C for 24 hr to allow cell attachment. Media was then 
removed and replaced with PRF-RPMI & 5% CSS containing either 1,25D (10nM), 
EB1089 (10nM), or vehicle control. Following incubation for 24 hr at 37°C, media was 
replenished with CSS/PRF-RPMI containing vehicle with, 1,25D (10nM) or EB1089 
(10nM) and/or DHEA (100M) treatments. Cells were incubated for a further 24 hours, 
before media was collected for metabolomic analysis, with cells trypsinized and pelleted 
for subsequent gene expression analysis. For RTV treated cells, the same conditions 
were used above, with a 24-hour pre-treatment of vehicle (ethanol) or 1,25D (10nM) and 
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then the addition of DHEA (100M) in fresh media, but included addition of RTV (100nM) 
during DHEA incubation period, and media was collected for analysis after 24 hrs. 
Biological inhibitor assays involved 24 hr incubation of cells in CSS/PRF-RPM, 
containing 100M DHEA in combination with either finasteride (10M), 2,4-DBP (2M) or 
vehicle control (DMSO), with media collected and analyzed.  
2.3. Steroid extraction and in-situ chemical derivatisation from cell media  
Media was removed from culture flasks at the specified time point after initiation of 
treatment and samples were extracted using Liquid-Liquid Extraction (LLE) with ethyl 
acetate. 750L of centrifuged cell media was added to 250L of water, 0.5ml 2M NaCl 
and spiked with internal standard (100M Testosterone-2,3,4-13C3). Then, 2mL ethyl 
acetate was added, vortexed for 10 seconds and left to separate in an ice bath for 20 
mins. An aliquot (1ml) of the supernatant was removed and dried down under N2 gas at 
RT. Samples were reconstituted with 100L of Girard-T (1mg/ml in MeOH) and 50L of 
acetic acid, vortexed for 3s and left on a heat block at 40°C for 60 mins. Then, 50L of 
water was added after reaction completion. Samples were then transferred to an HPLC 
amber vial insert for analysis. Matrix preparation and spotting: Matrix was applied using 
the dried droplet technique. In brief, 50L of the derivatized samples was mixed with 
50L of CHCA (α-Cyano-4-hydroxycinnamic acid) matrix (10mg/ml in 80% ACN with 
0.1% TFA). Vortexed for 2s and 1.0 L was spotted on a Bruker anchor MALDI target for 
Fourier Transform Ion Cyclotron Mass Spectrometry (FTICR-MS) analysis. 
2.4. Matrix Assisted Laser Desorption Ionization coupled with High 
Resolution Mass Spectrometry (MALDI-FTICR-MS) analysis of steroid 
metabolism  
Mass Spectrometry analysis was performed using a 12T SolariX MALDI- FTICR-MS 
(Bruker Daltonics, MA, US) employing a Smartbeam 1 kHz laser, with instrument control 
using SolariX control v1.5.0 (build 42.8) was used. Ions were accumulated across 800 
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laser shots and laser power was optimized for consistent ion production. Ions were 
detected using constant accumulation of selected ions (CASI) in positive ion mode. 
Isolation windows were set at (m/z 415.1 ± 50 Da) and (m/z 515 ± 50 Da) to include all 
targeted Gir-T androgens derivatives with an isolation time of 120s yielding a 4 Mword 
time-domain transient. Collision energies were optimized for optimal daughter ions 
production of ketosteroids Girard-T derivatives as outlined in Table S2. Mass calibration 
was performed using 13C labelled testosterone derivative (ISTD) at m/z 405.3270 using 
single point correction algorithm. Processing was performed using Data Analysis 4.4 built 
(Bruker Daltonics, Bremen, Germany). The product ions were identified using an error 
tolerance of 5 ppm for their corresponding theoretical monoisotopic masses. Data was 
reported as ratios as previously performed by Cobice et al. [24,25]. Fragmentation 
patterns were proposed and confirmed by accurate mass measurements (Figure S6). 
2.5. Statistical Analysis  
Data analysis for metabolite conversions was performed using SPSS (version 25), IBM, 
US. Data are expressed as mean ± SEM of three independent experiments, and 
differences were analyzed using one-way ANOVA with a Tukey post-hoc test. Statistical 
significance was accepted at p<0.05. Gene expression results were analyzed using a 
Microsoft Excel (version 16), using unpaired Student t-test. Statistical significance was 
accepted at p<0.05, or otherwise indicated.  
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3. Results 
3.1. Activation of VDR within prostate cancer cells results in a reduced 
metabolic conversion of DHEA to Testosterone and 
Dihydrotestosterone 
Mass spectrometry analysis was performed to quantitate changes within the CRPC 
androgen biosynthetic pathway within LNCaP cells that result from exposure to vitamin 
D-based treatments. Data depicted in Figure 2a revealed significant fluctuations in the 
‘flow’ between components comprising this intracrine network. While conversion of 
DHEA to A4 is not affected by addition of VDR ligands, there is a significant increase in 
HydroxyDHEA detected between treatments.  Exposure to 1,25D increases the 
production of HydroxyDHEA by approximately 2-fold, with EB1089 achieving a 6-fold 
elevation in the production of this metabolite, consistent with our previous studies [19]. 
Following the A4 conversion from DHEA (Figure 2b), differences were noted in the 
levels of testosterone and DHT. Induction of VDR within LNCaP cells using 1,25D or 
EB1089, resulted in a reduction the levels of testosterone by approximately 30% or 50% 
respectively. Similar effects of VDR activation were observed for the metabolic 
conversion of DHT, with the most significant effects found for EB1089 in lowering DHT to 
less than 50% of the levels detected in the control group. The levels of 5α-
androstanedione were also reduced with 1,25D and EB1089 achieving similar effects. In 
contrast, hydroxytestosterone was increased 2-fold following addition of VDR activating 
ligands, in accordance with our previous reports [18,19].  
To further explore a mechanistic basis, the impact of VDR ligand activation was 
investigated upon the expression of key metabolism-related genes (Figure S7 and 
Figure S8). This data shows the responsive changes in mRNA encoding CYP3A gene 
that follow in LNCaP cells cultured in the presence of DHEA, and VDR activation by 
addition of 1,25D. In the presence of 1,25D, the expression of both CYP3A4 and 
CYP3A5 was elevated. However, upon combined treatment, strikingly opposing 
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transcriptional responses were noted for both genes. This treatment achieved an 
increase in CYP3A4 expression but at a level that was reduced compared to 1,25D by 
itself. In contrast, DHEA shown a co-operative enhancement of CYP3A5 expression with 
1,25D. Other key genes, such as HSD-17β2, HSD-3β1, HSD-17β3, AKR1C3, SRD-51, 
and SRD-52 were assessed under the same liganded conditions for mRNA expression 
(Figure S8). Expression of HSD-17β2 is key to note, as it was unresponsive to 1,25D as 
previously observed [26], but applied combination of 1,25D with DHEA resulted in a 
striking co-operative induction (Figure S8b). 
3.2. CYP3A enzyme activity significantly contributes to the metabolic 
inactivation of Testosterone and Dihydrotestosterone within prostate 
cancer cells 
Contribution of the specific encoding enzymatic function was also assessed upon the 
metabolic flux within the CRPC pathway as shown in Figure 3. A CYP3A enzyme 
inhibitor, ritonavir (RTV) was used. DHEA with and without RTV displayed no metabolic 
flux, except from a slight increase of A4, indicating RTV was directly involved at the initial 
steps of the CRPC metabolic pathway.  
For A4 and hydroxy-DHEA, no significant changes were observed across treatments 
(Figure 3a). Data depicted within Figure 3b show that testosterone is largely affected by 
the addition of RTV and levels were lowered to vehicle (DHEA) upon addition of Vit D. 
Same trend was detected with DHT, showing significantly higher levels when RTV was 
added. Upon RTV and DHEA/VitD, DHT levels were significantly increased and level of 
hydroxylated testosterone were decreased in presence of either RTV or (RTV/VitD) 
treatments.  
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3.3. Assessment of biological model and analytical platforms by inhibition 
of SRD5α and HSD-17β enzymes 
To validate biological and analytical model platforms, experiments involving addition of 
finasteride or 2,4-dihydroxybenzophenone (2,4-DBP) were performed. These 
compounds represent an established pharmacological manipulation of the CRPC 
intracrine pathway, targeting inhibition of SRD5α and HSD-17β3 enzymes, respectively.  
As shown in Figure 4, levels of A4 were significantly higher in samples containing either 
of the two inhibitors compared to DHEA treatment. T levels increased upon finasteride 
treatment against control (~30%) and 2,4-DBP (~50%). Consequent to 2,4-DBP 
treatment, testosterone levels were decreased, and opposite effects were observed in 
5α-dione. 5α-dione and DHT levels were significantly reduced with finasteride and both 
steroids increased upon 2,4-DBP treatment. Hydroxytestosterone follows a mild trend 
with its testosterone precursor, as both finasteride and 2,4-DBP treated cells levels were 
increased. 
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4. Discussion  
Here, the effects of ligand activated VDR upon metabolic pathways are studied within 
LNCaP prostate cancer cells, with specific focus on the metabolic intracrine conversions 
of exogenously added DHEA. DHEA is considered the main circulatory precursor 
contributing to the synthesis of testosterone (T) and dihydrotestosterone (DHT) [27].  
While LNCaP cells are considered androgen-dependent, they also harbor a mutated 
form of AR that can be activated by DHEA and other metabolites within the androgen 
biosynthetic pathway [28] and therefore used in this study as representative of tumor 
phenotypes that potentially respond to adrenal sourced and intracrine-derived 
compounds during of the course of ADT. Our previous reports have detailed intracrine-
related effects of vitamin D within a range of prostate cancer (LNCaP, LAPC4, PC3, 
DU145) and non-tumorigenic prostate cells (RWPE1) which collectively stress such 
VDR-mediated effects are requisite upon co-expression of AR [18,19], highlighting 
intriguing interactions between the vitamin D and androgen hormonal pathways.  We 
have demonstrated that ligand-activated VDR within LNCaP cells has significant impact 
upon the intracrine conversion of DHEA to androgen-based metabolites.  
 
This was established by using a MALDI-FTICR-MS analytical platform developed in this 
study as a high throughput assay. The ultrahigh resolution of FTICR-MS in combination 
with collision induced dissociation (CID) and Isotopic Fine Structure (IFS) features 
provided high-confidence molecular formulas assignments for targeted androgens, 
resulting in unmatched accuracy for compound identification without the need of 
chromatography separation (Figure S2-S5). The use of CID/IFS in combination of Girard 
T derivatization provided unique selectivity as fragmentation can distinguish between A 
and D ring keto steroids via six- or five-member ring rearrangements of the hydrazine 
moiety respectively (Figure S6).  
In this study, VDR activation is also shown to diminish levels of the primary AR activating 
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ligands T and DHT (Figure 2 and 3). Both 1,25D and EB1089 treatments also 
significantly reduced the levels of 5α-dione, T and DHT, while increasing the levels of the 
inactive hydroxylated form of T. Several downstream effects of VDR activation potentially 
explain these observations. VDR mediates the increased expressions of CYP3A4 and 
CYP3A5, as displayed in Figure S7, leading to increased oxidative inactivation and 
levels of the biologically inactive hydroxylated forms of T and DHEA, confirming our 
previous observations [19]. Such hydroxylation events of one or more of these steroids 
may result in overall reduced levels of interconversion and metabolic ‘flux’ within the 
CRPC pathway. The reduced bioavailability of androgens to initiate AR mediated 
responses may contribute to prevent  disease relapse and emergence of an ADT-
resistant tumor [29,30]. The co-operative upregulation of HSD-17β2 following exposure 
to both 1,25D and DHEA (Figure S8) may reflect activation of both AR and VDR 
activation that leads to a favored conversion of T and DHT to A4 and 5-dione, 
respectively, will partly drive the pathway in a desired direction away from the potent 
ligands. Chang et al has shown that the CRPC pathway follows the ‘DHT backdoor 
pathway’ (DHEAA45α-dioneDHT) with 5α-dione being the main driver of growth 
for prostate cancer cell lines, when dosed with A4 against T [10]. In this study, the focus 
area was narrowed to the reactions highlighted in Figure 1 as steroidogenesis is 
extensive and multi levelled, with various enzyme families involved. We have suggested 
that the reduced levels of T that result from 1,25D treatment can largely be attributed to 
generation of hydroxylated T or the interconversion of other metabolites within the 
CRPC. Lundgvist et al 2011 however also described an up-regulation of CYP19A1 
(aromatase) mRNA within LNCaP cells in response to 1,25D. This may imply that a 
proportion of the testosterone involved in our system may also be converted to estradiol 
within our experiments [17]. Due to the complexity of steroidogenesis within prostatic 
cancer cells, many intermediate and further conversion metabolites may influence the 
fluctuation of measured analytes.  
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Finally, we have applied enzyme inhibitors finasteride and 2,4-dihydroxybenzophenone 
(2,4-DBP) (Figure 4) to demonstrate the system we used produced an expected 
alteration of the steroid metabolites. Finasteride was used to inhibit the SRD5α1/2 
enzyme and 2,4-DBP for the inhibition HSD-17β3, and so partially altering the levels of 
the relevant interconvertible targeted androgens. Advanced progression of prostate 
cancer to a ‘castrate resistant’ form is complex, with multi-interacting networks 
contributing to the emergence and continued growth of the tumor. While current ADT 
approaches may not realize a long term and absolute depletion of tumoral androgens or 
AR activating steroids, our current data provide further support for the co-application of a 
vitamin D-based regime as a means to counter contribution of intracrine pathways 
towards disease relapse.   
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7. Figure legends: 
Figure 1: Main Castrate resistant prostate cancer (CRPC) androgen pathway. 
DHEA: Dehydroepiandrosterone, T: Testosterone, A4: Androstenedione, 5α-dione: 5α -
Androstanedione, DHT: Dihydrotestosterone. 
 
Figure 2: Activation of VDR within prostate cancer cells results in a reduced 
metabolic conversion of DHEA to Testosterone and Dihydrotestosterone. LNCaP 
cells were treated within steroid free media with vehicle control, 10nM 1,25D or 10nM 
EB1089 for a 24-hour treatment period. After the initial 24-hour period, media was 
refreshed with the addition of the VDR ligand treatments and 100M of DHEA was 
introduced to the cell media for a steroid induced environment for a further 24-hour 
period. Data reveal that in comparison to control groups, treatment with 1,25D or the 
synthetic agonist EB1089 elicits significant fluctuations in the ‘flow’ between components 
comprising in this intracrine network.  a) Conversion percentage levels of DHEA to A4 by 
addition of VDR ligands. b) As A4 is a superior precursor of the CRPC pathway following 
the initial reaction, other metabolites of the pathway are expressed as a conversion from 
A4. The major conversion differences are noted in the levels of testosterone and DHT. 
Data are mean ± SEM. p<0.05*, p<0.01**, p<0.001***. 
 
Figure 3: Metabolic effect of the activation and inhibition of CYP3A enzymes. 
LNCaP cells were treated with vehicle, 10nM 1,25D, 100nM RTV or 10nM 1,25D and 
100nM RTV for 24 hours in steroid depleted media. The following 24-hour period 
introduced the same treatments and 100M DHEA for a steroid induced environment. 
Media from this experiment was derivatized as previously described in section 2.4.  
a) Percentage level conversion of A4 and hydroxy-DHEA from DHEA b) Metabolic 
conversion levels of CRPC steroids from A4. Data are mean ± SEM. p<0.05*, p<0.01**, 
p<0.001***. 
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Figure 4: Assessment of biological model and analytical platforms by inhibition of 
SRD5α and HSD-17β enzymes. LNCaP cells were treated using known enzyme 
inhibitors of HSD-17β3 (2,4-dihydroxybenzophenone) and SRD5α enzymes (finasteride). 
Under steroid free conditions for 24 hours, LNCaP cells were allowed to grow, then 
treated with vehicle control, 10M finasteride or 2M 2,4-DBP, along with each of the 
treatment sets being dosed with 100M DHEA for a further 24-hour period. a) 
Conversion levels of A4 are shown from the precursor DHEA b) Other steroid 
metabolites are displayed in conversion percentage from A4. Data are mean ± SEM. 
p<0.05*, p<0.01**, p<0.001*** 
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Figure 1: Smith et al., 2019
Figure 2: Smith et al., 2019
A4 Hydroxy-DHEA Hydroxy-T5α-dioneT DHT
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Figure 3: Smith et al., 2019
A4 Hydroxy-DHEA 5α-dione Hydroxy-TT DHT
Figure 4: Smith et al., 2019
A4 5α-androstane Hydroxy-TT DHT
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